Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.50 |
| ▸ | CA2 | P00918 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525150 | 0.81 | CA12 (0.56) | CA1CA2CA12CA9CA4 | |
| SCHEMBL3306193 | 0.80 | ALDH1A1 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL18647502 | 0.79 | IDO1 (0.51) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL18647501 | 0.78 | IDO1 (0.50) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL20759346 | 0.78 | IDO1 (0.50) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL8457758 | 0.78 | IDO1 (0.62) | CA1CA2CA12CA9IDO1 | |
| SCHEMBL18647826 | 0.77 | IDO1 (0.49) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL4047490 | 0.76 | CA12 (0.54) | CA1CA2CA12CA9CA4 | |
| SCHEMBL26385412 | 0.76 | IDO1 (0.48) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL3307021 | 0.75 | DPP8 (0.49) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2061751-A1 | NITRATE ESTERS OF AMINOALCOHOLS | Novartis Ag (CH) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | NOS2, NOS1, NOS3 | CA1 4310/4885CA2 2054/4885CA12 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.